SES
15.7.2021 08:52:09 CEST | Business Wire | Press release
Communities living across the eastern most peninsula of Africa will be able to enjoy 4G services on their mobile phones following a three-year partnership agreement signed by fixed satellite solution and professional service provider, iSAT Africa and SES, the leader in global content connectivity solutions. The two companies announced today that this new service will be available first via SES’s O3b medium earth orbit (MEO) constellation to subsequently migrate and expanded to SES’s next-generation MEO system, O3b mPOWER, in 2022.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210714005981/en/
iSAT Africa is well-established in the region for embracing innovative mobile internet connectivity solutions for unconnected rural communities in Africa. Through SES’s highly-flexible and scalable O3b mPOWER system that can deliver low-latency high-speed connectivity services from tens of megabits to multiple gigabits per second to a single site, iSAT Africa will be able to quickly scale its network to meet anticipated extensive connectivity demands. The fibre-like connectivity will equipe iSAT Africa to enable local mobile operators to deploy 4G services to close the digital divide. iSAT Africa is among the first companies in Africa to sign up for O3b mPOWER.
According to the GSMA 2020 report, mobile coverage has been expanding in Sub-Saharan Africa quickly; 3G coverage expanded to 75% compared to 63% in 2017, while 4G doubled to nearly 50% compared to 2017. However, the coverage gap in Sub-Saharan Africa remains the highest globally as it is home to 67% of the world’s population not covered by mobile broadband. This is because attempts to deploy 4G networks in sparsely-populated rural and remote areas continue to be an economic challenge. With telcos and internet service providers increasingly seeking innovative, cost-effective yet reliable connectivity solutions, SES’s MEO satellite-based MEF-certified service that can ensure seamless interconnectivity with any network is an ideal solution.
“At iSAT Africa, we don’t just believe in delivering connectivity to everyone across Africa. It’s also about delivering differentiated, cost-effective and reliable services that will enable various businesses to expand. This agreement represents a leap towards achieving that mission with iSAT Africa being able to deliver 4G services to communities and businesses located in underserved areas. As long-term partners of SES, we are confident this innovative solution will enable us to offer differentiated connectivity services to our telco customers,” said Rakesh Kukreja, Founder and Managing Director at iSAT Africa.
John-Paul Hemingway, CEO of SES Networks said, “We will be able to revolutionise the connectivity capabilities of mobile operators across Africa together through this agreement with iSAT Africa. The O3b and O3b mPOWER systems will easily enable the deployment of 4G services and high-performance networks for cloud applications regardless of where they are across the region. The enhanced flexibility and scalability of O3b mPOWER will truly connect Africans living in underserved areas in the most economically viable manner.”
Follow us on:
Twitter , Facebook , YouTube , LinkedIn , Instagram
Read our Blogs >
Visit the Media Gallery >
About SES
SES has a bold vision to deliver amazing experiences everywhere on earth by distributing the highest quality video content and providing seamless connectivity around the world. As the leader in global content connectivity solutions, SES operates the world’s only multi-orbit constellation of satellites with the unique combination of global coverage and high performance, including the commercially-proven, low-latency Medium Earth Orbit O3b system. By leveraging a vast and intelligent, cloud-enabled network, SES is able to deliver high-quality connectivity solutions anywhere on land, at sea or in the air, and is a trusted partner to the world’s leading telecommunications companies, mobile network operators, governments, connectivity and cloud service providers, broadcasters, video platform operators and content owners. SES’s video network carries over 8,200 channels and has an unparalleled reach of 361 million households, delivering managed media services for both linear and non-linear content. The company is listed on Paris and Luxembourg stock exchanges (Ticker: SESG). Further information is available at: www.ses.com .
About iSAT Africa
iSAT Africa, a fast-growing communication service provider in Africa and Middle East, is a UAE based company whose mission is to transform the way Africa gets and stays connected with the rest of the world. iSAT’s unique connectivity solutions deliver efficiency, reliability and affordability for Data, Internet, Voice and Video solutions . These customized solutions serve broadcast and media organizations, multinationals, major ISPs, Governmental and Non-Governmental organizations as well as Tier 1 telecom operators.
With its network of partners and service providers, iSAT Africa is able to satisfactorily deliver end-to-end solutions, turn-key solutions and managed services to it’s customers/ partners within the shortest time possible whilst adhering to agreed upon service level agreements.
iSAT’s Satellite Solutions, backed by powerful satellites, teleport and data infrastructure, latest technologies and inhouse human expertise is very unique in the industry. It is against this background that iSAT Africa partners with other leaders within the telco space in a bid to adequately meet its customers ever growing demand for telecommunication services across the African continent.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210714005981/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom